Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shot every 4 weeks replace weekly blood filtering for High-Risk heart patients?

NCT ID NCT05305664

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests an experimental drug called pelacarsen in people with very high levels of lipoprotein(a), a type of cholesterol linked to heart disease. Participants currently undergo weekly blood-filtering treatments (apheresis) to lower their Lp(a). The trial aims to see if taking pelacarsen as a shot every four weeks can reduce how often they need these sessions. It involves about 50 adults in Germany who have both high Lp(a) and established cardiovascular disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called pelacarsen (TQJ230) given as a shot under the skin every 4 weeks
What this could lead to
If successful, pelacarsen could free people with high Lp(a) from weekly blood-filtering sessions, simplifying their care and reducing treatment burden.
What could go wrong
This is a mid-stage trial with only 51 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPOPROTEINEMIA(A) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder hyperlipoproteinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPOPROTEINEMIA(A)

Contacts and locations

Locations

  • Novartis Investigative Site

    Villingen-Schwenningen, Baden-Wurttemberg, 78052, Germany

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60431, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075, Germany

  • Novartis Investigative Site

    Düsseldorf, North Rhine-Westphalia, 42010, Germany

  • Novartis Investigative Site

    Geilenkirchen, North Rhine-Westphalia, 52511, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Cloppenburg, 49661, Germany

  • Novartis Investigative Site

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.